196 related articles for article (PubMed ID: 21093860)
1. Evaluation of anti-atherosclerotic activities of PPAR-α, PPAR-γ, and LXR agonists in hyperlipidemic atherosclerosis-susceptible F(1)B hamsters.
Srivastava RA
Atherosclerosis; 2011 Jan; 214(1):86-93. PubMed ID: 21093860
[TBL] [Abstract][Full Text] [Related]
2. Anti-hyperlipidemic and insulin sensitizing activities of fenofibrate reduces aortic lipid deposition in hyperlipidemic Golden Syrian hamster.
Srivastava RA; He S
Mol Cell Biochem; 2010 Dec; 345(1-2):197-206. PubMed ID: 20740305
[TBL] [Abstract][Full Text] [Related]
3. Fenofibrate ameliorates diabetic and dyslipidemic profiles in KKAy mice partly via down-regulation of 11beta-HSD1, PEPCK and DGAT2. Comparison of PPARalpha, PPARgamma, and liver x receptor agonists.
Srivastava RA
Eur J Pharmacol; 2009 Apr; 607(1-3):258-63. PubMed ID: 19245804
[TBL] [Abstract][Full Text] [Related]
4. Synthetic LXR agonist inhibits the development of atherosclerosis in New Zealand White rabbits.
Honzumi S; Shima A; Hiroshima A; Koieyama T; Terasaka N
Biochim Biophys Acta; 2011 Dec; 1811(12):1136-45. PubMed ID: 21875689
[TBL] [Abstract][Full Text] [Related]
5. NPC1L1 and ABCG5/8 induction explain synergistic fecal cholesterol excretion in ob/ob mice co-treated with PPAR-α and LXR agonists.
Srivastava RAK; Cefalu AB; Srivastava NS; Averna M
Mol Cell Biochem; 2020 Oct; 473(1-2):247-262. PubMed ID: 32661772
[TBL] [Abstract][Full Text] [Related]
6. A peroxisome proliferator-activated receptor alpha/gamma dual agonist with a unique in vitro profile and potent glucose and lipid effects in rodent models of type 2 diabetes and dyslipidemia.
Reifel-Miller A; Otto K; Hawkins E; Barr R; Bensch WR; Bull C; Dana S; Klausing K; Martin JA; Rafaeloff-Phail R; Rafizadeh-Montrose C; Rhodes G; Robey R; Rojo I; Rungta D; Snyder D; Wilbur K; Zhang T; Zink R; Warshawsky A; Brozinick JT
Mol Endocrinol; 2005 Jun; 19(6):1593-605. PubMed ID: 15831517
[TBL] [Abstract][Full Text] [Related]
7. A systems biology approach to the hepatic role of the oxysterol receptor LXR in the regulation of lipogenesis highlights a cross-talk with PPARα.
Ducheix S; Podechard N; Lasserre F; Polizzi A; Pommier A; Murzilli S; Di Lisio C; D'Amore S; Bertrand-Michel J; Montagner A; Pineau T; Loiseau N; Lobaccaro JM; Martin PG; Guillou H
Biochimie; 2013 Mar; 95(3):556-67. PubMed ID: 23063693
[TBL] [Abstract][Full Text] [Related]
8. PPAR agonist-induced reduction of Mcp1 in atherosclerotic plaques of obese, insulin-resistant mice depends on adiponectin-induced Irak3 expression.
Hulsmans M; Geeraert B; Arnould T; Tsatsanis C; Holvoet P
PLoS One; 2013; 8(4):e62253. PubMed ID: 23620818
[TBL] [Abstract][Full Text] [Related]
9. Concurrent activation of liver X receptor and peroxisome proliferator-activated receptor alpha exacerbates hepatic steatosis in high fat diet-induced obese mice.
Gao M; Bu L; Ma Y; Liu D
PLoS One; 2013; 8(6):e65641. PubMed ID: 23762402
[TBL] [Abstract][Full Text] [Related]
10. Liver X receptor agonist T0901317 reduces atherosclerotic lesions in apoE-/- mice by up-regulating NPC1 expression.
Ou X; Dai X; Long Z; Tang Y; Cao D; Hao X; Hu Y; Li X; Tang C
Sci China C Life Sci; 2008 May; 51(5):418-29. PubMed ID: 18785587
[TBL] [Abstract][Full Text] [Related]
11. Activation of liver X receptor decreases atherosclerosis in Ldlr⁻/⁻ mice in the absence of ATP-binding cassette transporters A1 and G1 in myeloid cells.
Kappus MS; Murphy AJ; Abramowicz S; Ntonga V; Welch CL; Tall AR; Westerterp M
Arterioscler Thromb Vasc Biol; 2014 Feb; 34(2):279-84. PubMed ID: 24311381
[TBL] [Abstract][Full Text] [Related]
12. LXR agonist suppresses atherosclerotic lesion growth and promotes lesion regression in apoE*3Leiden mice: time course and mechanisms.
Verschuren L; de Vries-van der Weij J; Zadelaar S; Kleemann R; Kooistra T
J Lipid Res; 2009 Feb; 50(2):301-11. PubMed ID: 18757914
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of notch enhances the anti-atherosclerotic effects of LXR agonists while reducing fatty liver development in ApoE-deficient mice.
Hao Y; Wang X; Zhang F; Wang M; Wang Y; Wang H; Du Y; Wang T; Fu F; Gao Z; Zhang L
Toxicol Appl Pharmacol; 2020 Nov; 406():115211. PubMed ID: 32853627
[TBL] [Abstract][Full Text] [Related]
14. Liver X receptor agonist methyl-3β-hydroxy-5α,6α-epoxycholanate attenuates atherosclerosis in apolipoprotein E knockout mice without increasing plasma triglyceride.
Yan W; Zhang T; Cheng J; Zhou X; Qu X; Hu H
Pharmacology; 2010; 86(5-6):306-12. PubMed ID: 21071998
[TBL] [Abstract][Full Text] [Related]
15. Elimination of macrophages drives LXR-induced regression both in initial and advanced stages of atherosclerotic lesion development.
van der Stoep M; Li Z; Calpe-Berdiel L; van der Sluis RJ; Saleh P; McKinnon HJ; Smit MJ; Korporaal SJ; Van Berkel TJ; Van Eck M; Hoekstra M
Biochem Pharmacol; 2013 Dec; 86(11):1594-602. PubMed ID: 24095721
[TBL] [Abstract][Full Text] [Related]
16. Liver LXRα expression is crucial for whole body cholesterol homeostasis and reverse cholesterol transport in mice.
Zhang Y; Breevoort SR; Angdisen J; Fu M; Schmidt DR; Holmstrom SR; Kliewer SA; Mangelsdorf DJ; Schulman IG
J Clin Invest; 2012 May; 122(5):1688-99. PubMed ID: 22484817
[TBL] [Abstract][Full Text] [Related]
17. The effect of dual PPAR alpha/gamma stimulation with combination of rosiglitazone and fenofibrate on metabolic parameters in type 2 diabetic patients.
Seber S; Ucak S; Basat O; Altuntas Y
Diabetes Res Clin Pract; 2006 Jan; 71(1):52-8. PubMed ID: 16009445
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of ERK1/2 and activation of LXR synergistically reduce atherosclerotic lesions in ApoE-deficient mice.
Chen Y; Duan Y; Yang X; Sun L; Liu M; Wang Q; Ma X; Zhang W; Li X; Hu W; Miao RQ; Xiang R; Hajjar DP; Han J
Arterioscler Thromb Vasc Biol; 2015 Apr; 35(4):948-59. PubMed ID: 25810299
[TBL] [Abstract][Full Text] [Related]
19. Effects of high dietary fat and cholesterol on expression of PPAR alpha, LXR alpha, and their responsive genes in the liver of apoE and LDLR double deficient mice.
Zou Y; Du H; Yin M; Zhang L; Mao L; Xiao N; Ren G; Zhang C; Pan J
Mol Cell Biochem; 2009 Mar; 323(1-2):195-205. PubMed ID: 19067122
[TBL] [Abstract][Full Text] [Related]
20. A systems biology approach reveals the physiological origin of hepatic steatosis induced by liver X receptor activation.
Hijmans BS; Tiemann CA; Grefhorst A; Boesjes M; van Dijk TH; Tietge UJ; Kuipers F; van Riel NA; Groen AK; Oosterveer MH
FASEB J; 2015 Apr; 29(4):1153-64. PubMed ID: 25477282
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]